Why didn't Medtronic recall sooner?

Big cardiac clinics across the country stopped using Medtronic's Fidelis defibrillator lead in early February because they considered it unsafe. So why did the company wait till October to recall it? And why did it blame doctors' technique for some of the malfunctions?

Those are the questions the Wall Street Journal poses today in a piece that not only questions Medtronic's actions, but also the FDA's system for regulating medical devices, which aren't subject to the stringent testing prescription drugs undergo before hitting the market.

- read the article in the Wall Street Journal (sub. req.)

Related Articles:
Medtronic recall spawns inquiry. Report
Did patient lawsuit spur Medtronic recall? Report
Medtronic withdraws defibrillator part. Report
Medtronic's fortunes depend on new stent. Report

Suggested Articles

Despite having lost some of its novelty, AZ's Brilinta is touting bleeding data over aspirin that could be a big break in acute coronary syndrome.

More than a year after J&J and Bayer pulled the plug on Xarelto in patients after a rare valve replacement, the pair are still seeking answers.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.